{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:03:54Z","timestamp":1789427034459,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100030974","name":"Pavol Jozef \u0160af\u00e1rik University in Ko\u0161ice","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030974","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pancreatic ductal adenocarcinoma (PDAC) is most often diagnosed at an advanced stage, when distant metastases are already present and curative treatment options are limited. In this clinical context, biomarkers capable of reflecting tumor aggressiveness and metastatic potential are of particular relevance. Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been implicated in tumor invasion and metastatic dissemination; however, its clinical significance in pancreatic cancer remains incompletely defined. We analyzed TIMP-1 concentrations in serum and pancreatic tissue of 154 patients (108 malignant tumors, 46 benign lesions) using ELISA. Associations with clinical stage and the presence of distant metastases were assessed using non-parametric tests and ROC curve analysis. TIMP-1 levels were significantly higher in malignant compared with benign tumors, both in tissue (24.28 vs. 21.62 ng\/mL;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0318) and serum (28.03 vs. 25.52 ng\/mL;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0106). Serum TIMP-1 showed superior diagnostic accuracy (AUC\u2009=\u20090.796) compared to tissue TIMP-1 (AUC\u2009=\u20090.745). Patients with distant metastases exhibited significantly higher serum TIMP-1 levels than non-metastatic cases (28.33 vs. 26.53 ng\/mL;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0046; AUC\u2009=\u20090.785). Serum TIMP-1 is associated with malignant and metastatic pancreatic disease and reflects a more aggressive tumor phenotype in patients with established pancreatic cancer. While the observed differences are modest and limit its applicability as a stand-alone diagnostic or screening biomarker, TIMP-1 may provide clinically relevant information regarding metastatic status and could contribute to prognostic stratification or multimarker approaches in pancreatic cancer.\n                  <\/jats:p>","DOI":"10.1007\/s10238-026-02241-0","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:24:03Z","timestamp":1782588243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum TIMP-1 shows a potential association with metastatic disease in patients with pancreatic cancer: a pilot analysis without a healthy control cohort"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1600-4116","authenticated-orcid":false,"given":"Ivana","family":"Vecurkovska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3396-0488","authenticated-orcid":false,"given":"Veronika","family":"Roskovicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4770-987X","authenticated-orcid":false,"given":"Tomas","family":"Gajdzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-5547","authenticated-orcid":false,"given":"Marek","family":"Soltes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2786-0620","authenticated-orcid":false,"given":"Jana","family":"Maslankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2918-0183","authenticated-orcid":false,"given":"Ivana","family":"Kocanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5479-6444","authenticated-orcid":false,"given":"Jana","family":"Katuchova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"2241_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"2241_CR2","doi-asserted-by":"publisher","first-page":"e70162","DOI":"10.1002\/mco2.70162","volume":"6","author":"K Zhou","year":"2025","unstructured":"Zhou K, Liu Y, Tang C, Zhu H. Pancreatic Cancer: Pathogenesis and Clinical Studies. MedComm. 2025;6:e70162. https:\/\/doi.org\/10.1002\/mco2.70162.","journal-title":"MedComm"},{"key":"2241_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic Cancer: A Review. JAMA. 2021;326:851. https:\/\/doi.org\/10.1001\/jama.2021.13027.","journal-title":"JAMA"},{"key":"2241_CR4","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/cac2.12204","volume":"41","author":"J Yang","year":"2021","unstructured":"Yang J, Xu R, Wang C, et al. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Cancer Commun. 2021;41:1257\u201374. https:\/\/doi.org\/10.1002\/cac2.12204.","journal-title":"Cancer Commun"},{"key":"2241_CR5","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.3390\/ijms26083621","volume":"26","author":"P Ioannou","year":"2025","unstructured":"Ioannou P, Katsoulieris E, Afratis NA. Matrix Dynamics and Microbiome Crosstalk: Matrix Metalloproteinases as Key Players in Disease and Therapy. IJMS. 2025;26:3621. https:\/\/doi.org\/10.3390\/ijms26083621.","journal-title":"IJMS"},{"key":"2241_CR6","doi-asserted-by":"publisher","first-page":"110258","DOI":"10.1016\/j.jbc.2025.110258","volume":"301","author":"A Shoari","year":"2025","unstructured":"Shoari A, Coban MA, Hockla A, et al. Directed evolution of metalloproteinase inhibitor TIMP-1 for selective inhibition of MMP-9 exploits catalytic and fibronectin domain interactions. J Biol Chem. 2025;301:110258. https:\/\/doi.org\/10.1016\/j.jbc.2025.110258.","journal-title":"J Biol Chem"},{"key":"2241_CR7","doi-asserted-by":"publisher","first-page":"896099","DOI":"10.3389\/fmolb.2022.896099","volume":"9","author":"S Mustafa","year":"2022","unstructured":"Mustafa S, Koran S, AlOmair L. Insights Into the Role of Matrix Metalloproteinases in Cancer and its Various Therapeutic Aspects: A Review. Front Mol Biosci. 2022;9:896099. https:\/\/doi.org\/10.3389\/fmolb.2022.896099.","journal-title":"Front Mol Biosci"},{"key":"2241_CR8","doi-asserted-by":"publisher","first-page":"9739","DOI":"10.3390\/ijms21249739","volume":"21","author":"GA Cabral-Pacheco","year":"2020","unstructured":"Cabral-Pacheco GA, Garza-Veloz I, Castruita-De La Rosa C, et al. The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. IJMS. 2020;21:9739. https:\/\/doi.org\/10.3390\/ijms21249739.","journal-title":"IJMS"},{"key":"2241_CR9","doi-asserted-by":"publisher","first-page":"e20210911","DOI":"10.1084\/jem.20210911","volume":"218","author":"CD Hermann","year":"2021","unstructured":"Hermann CD, Schoeps B, Eckfeld C, et al. TIMP1 expression underlies sex disparity in liver metastasis and survival in pancreatic cancer. J Exp Med. 2021;218:e20210911. https:\/\/doi.org\/10.1084\/jem.20210911.","journal-title":"J Exp Med"},{"key":"2241_CR10","doi-asserted-by":"publisher","unstructured":"Liu Y, Zhang H, Wang Y, Li J, Chen X, Yang L, et al. Matrix metalloproteinase-11 promotes tumor progression and metastasis in pancreatic cancer via activation of the IGF1\/AKT pathway. Front Oncol. 2021;11:\u2013. https:\/\/doi.org\/10.3389\/fonc.2021.752238.","DOI":"10.3389\/fonc.2021.752238"},{"key":"2241_CR11","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.62347\/OVUJ4436","volume":"15","author":"Y-N Sung","year":"2025","unstructured":"Sung Y-N. Tissue inhibitor of metalloproteinase 1 as a biomarker of venous invasion in pancreatic ductal adenocarcinoma. Am J Cancer Res. 2025;15:1248\u201363. https:\/\/doi.org\/10.62347\/OVUJ4436.","journal-title":"Am J Cancer Res"},{"key":"2241_CR12","doi-asserted-by":"publisher","unstructured":"Fahrmann JF, Yip-Schneider M, Vykoukal J, et al. Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing. Cancer Lett. 2025;217450. https:\/\/doi.org\/10.1016\/j.canlet.2025.217450.","DOI":"10.1016\/j.canlet.2025.217450"},{"key":"2241_CR13","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.3390\/cancers17111866","volume":"17","author":"NA Palma","year":"2025","unstructured":"Palma NA, Lucas AL, Katona BW, et al. A High Performing Biomarker Signature for Detecting Early-Stage Pancreatic Ductal Adenocarcinoma in High-Risk Individuals. Cancers. 2025;17:1866. https:\/\/doi.org\/10.3390\/cancers17111866.","journal-title":"Cancers"},{"key":"2241_CR14","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1158\/0008-5472.CAN-20-4125","volume":"81","author":"B Schoeps","year":"2021","unstructured":"Schoeps B, Eckfeld C, Prokopchuk O, et al. TIMP1 Triggers Neutrophil Extracellular Trap Formation in Pancreatic Cancer. Cancer Res. 2021;81:3568\u201379. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-4125.","journal-title":"Cancer Res"},{"key":"2241_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12943-024-02207-4","volume":"24","author":"C-A Wang","year":"2025","unstructured":"Wang C-A, Hou Y-C, Hong Y-K, et al. Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells. Mol Cancer. 2025;24:25. https:\/\/doi.org\/10.1186\/s12943-024-02207-4.","journal-title":"Mol Cancer"},{"key":"2241_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215704","author":"Z Tian","year":"2022","unstructured":"Tian Z, et al. TIMP1 derived from pancreatic cancer cells stimulates Schwann cells and promotes the occurrence of perineural invasion. Cancer Lett. 2022. https:\/\/doi.org\/10.1016\/j.canlet.2022.215704.","journal-title":"Cancer Lett"},{"key":"2241_CR17","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.3390\/cancers14123028","volume":"14","author":"P Gumberger","year":"2022","unstructured":"Gumberger P, Bjornsson B, Sandstr\u00f6m P, et al. The Liver Pre-Metastatic Niche in Pancreatic Cancer: A Potential Opportunity for Intervention. Cancers. 2022;14:3028. https:\/\/doi.org\/10.3390\/cancers14123028.","journal-title":"Cancers"},{"issue":"1","key":"2241_CR18","doi-asserted-by":"publisher","first-page":"102546","DOI":"10.1016\/j.xcrm.2025.102546","volume":"20","author":"J Fr\u00e4drich","year":"2026","unstructured":"Fr\u00e4drich J, Reyes CM, Hendel M, et al. Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers. Cell Rep Med. 2026;20(1):102546. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12866174\/.","journal-title":"Cell Rep Med"},{"key":"2241_CR19","doi-asserted-by":"publisher","first-page":"101747","DOI":"10.1016\/j.eclinm.2022.101747","volume":"55","author":"LNC Boyd","year":"2023","unstructured":"Boyd LNC, Ali M, Leeflang MMG, et al. Diagnostic accuracy and added value of blood-based protein biomarkers for pancreatic cancer: a meta-analysis of aggregate and individual participant data. eClinicalMedicine. 2023;55:101747. link.","journal-title":"eClinicalMedicine"},{"issue":"24","key":"2241_CR20","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.3390\/diagnostics15243177","volume":"15","author":"R Pescatore","year":"2025","unstructured":"Pescatore R, Milliken N, King T, et al. Analytical Validation of a Serum Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Diagnostics (Basel). 2025;15(24):3177. https:\/\/doi.org\/10.3390\/diagnostics15243177.","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"2241_CR21","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/gutjnl-2023-331074","volume":"73","author":"R Ben-Ami","year":"2024","unstructured":"Ben-Ami R, Wang QL, Zhang J, et al. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut. 2024;73(4):639\u201348. https:\/\/doi.org\/10.1136\/gutjnl-2023-331074.","journal-title":"Gut"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02241-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02241-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02241-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:22:45Z","timestamp":1789424565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02241-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2241"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02241-0","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"332"}}